Floatz logo

4H-1-BENZOPYRAN-4-ONE, 7-((6-O-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)-.BETA.-D-GLUCOPYRANOSYL)OXY)-2,3-DIHYDO-5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-, (S)-

Metabolic Syndrome

University of Rome Tor VergataSmall moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

57 Active assets in the Metabolic Syndrome cohort.

Asset / SponsorPhaseRating
Lipitor
Seoul National University Hospital
Phase 4BBB
Metformin
Islamabad Medical and Dental College
Phase 4BBB
Pioglitazone
Philip Kern
Phase 4BBB
OLMESARTAN MEDOXOMIL
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Phase 4BBB
Rosuvastatin
Hamdard University
Phase 4BBB

View all 50 →

Same molecule, other indications

4H-1-BENZOPYRAN-4-ONE, 7-((6-O-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)-.BETA.-D-GLUCOPYRANOSYL)OXY)-2,3-DIHYDO-5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-, (S)- is also rated in:

post-operative wound seroma, non-human animalDormant
BB
Indicative ·
69 / 100
View asset →
pelvic congestion syndromeDormant
B
Indicative ·
60 / 100
View asset →
breast cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →